Meglumine antimoniate: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 22: | Line 22: | ||
''' [[Meglumine antimoniate description|Description]]''' | ''' [[Meglumine antimoniate description|Description]]''' | ||
'''| [[Meglumine antimoniate indications and usage|Indications and Usage]]''' | '''| [[Meglumine antimoniate indications and usage|Indications and Usage]]''' | ||
'''| [[Meglumine antimoniate contraindications|Contraindications]]''' | '''| [[Meglumine antimoniate contraindications|Contraindications]]''' | ||
'''| [[Meglumine antimoniate warnings and precautions|Warnings and Precautions]]''' | '''| [[Meglumine antimoniate warnings and precautions|Warnings and Precautions]]''' | ||
'''| [[Meglumine antimoniate adverse reactions|Adverse Reactions]]''' | '''| [[Meglumine antimoniate adverse reactions|Adverse Reactions]]''' | ||
'''| [[Meglumine antimoniate dosage and administration|Dosage and Administration]]''' | '''| [[Meglumine antimoniate dosage and administration|Dosage and Administration]]''' | ||
'''| [[Meglumine antimoniate how supplied|How Supplied]]''' | '''| [[Meglumine antimoniate how supplied|How Supplied]]''' | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
The mechanism of action of meglumine antimoniate is unknown, but may involve inhibition of the parasite's glycolytic and fatty acid oxidative activity resulting in decreased reducing equivalents for [[antioxidant]] defense and decreased synthesis of [[adenosine triphosphate]]. | |||
==References== | ==References== | ||
Latest revision as of 03:47, 7 January 2014
| Meglumine Antimoniate |
|---|
| GLUCANTIM® WHO Prescribing Information |
| Description |
| Indications and Usage |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Dosage and Administration |
| How Supplied |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: Meglumine antimonate
Overview
Meglumine antimoniate is a medicine used for treating leishmaniasis. It is manufactured by Aventis and sold as Glucantime in France, and Glucantim in Italy.
It belongs to a group of compounds known as the pentavalent antimonials. It is administered by intramuscular injection.
Category
Antiparasitic
Brand Names
GLUCANTIM®, GLUCANTIME® (NOT AVAILABLE)
WHO Model Prescribing Information
Description | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Dosage and Administration | How Supplied
Mechanism of Action
The mechanism of action of meglumine antimoniate is unknown, but may involve inhibition of the parasite's glycolytic and fatty acid oxidative activity resulting in decreased reducing equivalents for antioxidant defense and decreased synthesis of adenosine triphosphate.